Eli Lilly and Company announced earlier this week that its popular obesity drug, Zepbound (tirzepatide) outperformed rival ...

Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.

Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the branded drugs, Lilly on Wednesday said it would sell a version of Zepbound ...

Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...

Lilly's rival Danish firm Novo Nordisk is also working to bring its obesity drug Wegovy (Semaglutide) to India soon, and ...

Eli Lilly ( LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug Zepbound.

It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...

With Eli Lilly's diabetes and obesity products Mounjaro and Zepbound booming in popularity, the drugmaker finds itself in a ...

Eli Lilly And Co (NYSE:LLY) announced a $3 billion expansion of its Kenosha County, Wisconsin, manufacturing facility to ...

Eli Lilly, the US pharmaceutical giant that gained widespread attention globally with its weight-loss treatments, plans to ...